News Release

03/16/2023
Information
22nd Annual General Meeting of Shareholders Measures to Prevent the Spread of Covid 19
03/13/2023
Information
Impacts of Silicon Valley Bank closure
03/02/2023
Information
GNI Group summary Q&A from full-year 2022 financial results analyst call and other recent inquiries
01/13/2023
Information
Resuming normal office operations
01/11/2023
Information
2023 New Year Greeting
01/04/2023
Information
FAQ for Our Disclosure on December 27, 2022, "GNI Group and Catalyst Biosciences Signed Agreements to Advance Liver Fibrosis Drug Development"
12/20/2022
Information
Notice of COVID-19 infection of our employees and suspension of telephone reception
11/29/2022
Information
FY2022 Q3 Analyst Call Q&A Summary
08/25/2022
Information
FY2022 Q2 Analyst Call Q&A Summary
06/11/2022
Information
Chief Scientific Officer of Cullgen Inc. will be speaking at the 30th Annual Meeting of the Japanese Breast Cancer Society
06/11/2022
Information
Beijing Continent enrolls the first subject of pirfenidone capsules Phase III clinical trial for pneumoconiosis
05/24/2022
Information
FY2022 Q1 Analyst Call Q&A Summary
04/15/2022
Information
GNI Group FY2021 Annual General Meeting Q&A Summary
01/31/2022
Information
Frequently Asked Questions Updated File (2022-JAN-31)
01/31/2022
Information
Frequently Asked Questions Updated (2022-JAN-31)